The treatment of heart failure (HF) with reduced ejection fraction (HFrEF) has substantially
developed over the past decades. More than ever before, the application of appropriate …

The adoption of new pillars of heart failure therapy over the past decade has produced
enormous improvements in health outcomes, but it has also greatly increased health care …

Abstract Purpose of Review To discuss the prevailing racial and ethnic disparities in heart
failure (HF) care by identifying barriers to equitable care and proposing solutions for …

Approximately 3 decades ago, the standard of care for patients with heart failure with
reduced ejection fraction was digoxin and diuretics. 1 The path to defining guideline …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

Purpose Given known differences between real-world and clinical trial populations, we
characterized demographics, clinical characteristics, and outcomes using real-world (RW) …

Heart failure is a leading cause of morbidity and mortality globally. The natural history of
heart failure with reduced ejection fraction (HFrEF) has been altered with the development of …

High-quality, evidence-based policies represent an important medium for promoting and
improving cardiovascular health worldwide. Cardiovascular disease is among the highest …

Introduction: The efficacy and safety of emerging therapies for heart failure with reduced
ejection fraction (HFrEF) have never been compared in specific subgroups of patients …

Background Following the availability of new drugs for chronic heart failure (HF) with
reduced ejection fraction (HFrEF), we sought to provide an updated and comparative …